452 related articles for article (PubMed ID: 24467436)
1. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.
Sim E; Abuhammad A; Ryan A
Br J Pharmacol; 2014 Jun; 171(11):2705-25. PubMed ID: 24467436
[TBL] [Abstract][Full Text] [Related]
2. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A
Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012
[TBL] [Abstract][Full Text] [Related]
3. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function.
Sim E; Pinter K; Mushtaq A; Upton A; Sandy J; Bhakta S; Noble M
Biochem Soc Trans; 2003 Jun; 31(Pt 3):615-9. PubMed ID: 12773167
[TBL] [Abstract][Full Text] [Related]
4. Arylamine N-acetyltransferases: from structure to function.
Sim E; Walters K; Boukouvala S
Drug Metab Rev; 2008; 40(3):479-510. PubMed ID: 18642144
[TBL] [Abstract][Full Text] [Related]
5. Arylamine N-acetyltransferases--from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention.
Sim E; Fakis G; Laurieri N; Boukouvala S
Adv Pharmacol; 2012; 63():169-205. PubMed ID: 22776642
[TBL] [Abstract][Full Text] [Related]
6. Arylamine N-acetyltransferases: what we learn from genes and genomes.
Boukouvala S; Fakis G
Drug Metab Rev; 2005; 37(3):511-64. PubMed ID: 16257833
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human.
Tsirka T; Boukouvala S; Agianian B; Fakis G
Gene; 2014 Feb; 536(1):65-73. PubMed ID: 24333853
[TBL] [Abstract][Full Text] [Related]
8. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes.
Sim E; Payton M; Noble M; Minchin R
Hum Mol Genet; 2000 Oct; 9(16):2435-41. PubMed ID: 11005799
[TBL] [Abstract][Full Text] [Related]
9. Arylamine N-acetyltransferases in mycobacteria.
Sim E; Sandy J; Evangelopoulos D; Fullam E; Bhakta S; Westwood I; Krylova A; Lack N; Noble M
Curr Drug Metab; 2008 Jul; 9(6):510-9. PubMed ID: 18680471
[TBL] [Abstract][Full Text] [Related]
10. Molecular and Functional Characterization of
Uno Y; Uehara S; Ijiri M; Kawaguchi H; Asano A; Shiraishi M; Banju K; Murayama N; Yamazaki H
Drug Metab Dispos; 2022 Nov; 50(11):1429-1433. PubMed ID: 35768074
[TBL] [Abstract][Full Text] [Related]
11. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2.
Smelt VA; Mardon HJ; Sim E
Pharmacol Toxicol; 1998 Oct; 83(4):149-57. PubMed ID: 9820875
[TBL] [Abstract][Full Text] [Related]
12. The pharmacogenetics of NAT: structural aspects.
Pompeo F; Brooke E; Kawamura A; Mushtaq A; Sim E
Pharmacogenomics; 2002 Jan; 3(1):19-30. PubMed ID: 11966400
[TBL] [Abstract][Full Text] [Related]
13. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.
Laurieri N; Kawamura A; Westwood IM; Varney A; Morris E; Russell AJ; Stanley LA; Sim E
BMC Pharmacol Toxicol; 2014 Nov; 15():68. PubMed ID: 25432241
[TBL] [Abstract][Full Text] [Related]
14. Arylamine N-acetyltransferases - of mice, men and microorganisms.
Upton A; Johnson N; Sandy J; Sim E
Trends Pharmacol Sci; 2001 Mar; 22(3):140-6. PubMed ID: 11239577
[TBL] [Abstract][Full Text] [Related]
15. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.
Grant DM; Blum M; Beer M; Meyer UA
Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083
[TBL] [Abstract][Full Text] [Related]
16. Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism.
Upton AM; Mushtaq A; Victor TC; Sampson SL; Sandy J; Smith DM; van Helden PV; Sim E
Mol Microbiol; 2001 Oct; 42(2):309-17. PubMed ID: 11703656
[TBL] [Abstract][Full Text] [Related]
17. Arylamine N-acetyltransferases.
Sim E; Westwood I; Fullam E
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):169-84. PubMed ID: 17428149
[TBL] [Abstract][Full Text] [Related]
18. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.
Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM
Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847
[TBL] [Abstract][Full Text] [Related]
19. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.
Sugamori KS; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
Mol Pharmacol; 2003 Jul; 64(1):170-9. PubMed ID: 12815173
[TBL] [Abstract][Full Text] [Related]
20. Fusarium verticillioides NAT1 (FDB2) N-malonyltransferase is structurally, functionally and phylogenetically distinct from its N-acetyltransferase (NAT) homologues.
Karagianni EP; Kontomina E; Lowe ED; Athanasopoulos K; Papanikolaou G; Garefalaki V; Kotseli V; Zaliou S; Grimaud T; Arvaniti K; Tsatiri MA; Fakis G; Glenn AE; Roversi P; Abuhammad A; Ryan A; Sim RB; Sim E; Boukouvala S
FEBS J; 2023 May; 290(9):2412-2436. PubMed ID: 36178468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
